(a) The Issuer shall make the following information available to the Noteholders by way of press release and by publication on the website of the Issuer:
(ii) as soon as the same become available, but in any event within two (2) Months after the end of each quarter of its financial year, its consolidated financial statements or the year-end report (Sw: bokslutskommunike) (as applicable) for such period prepared in accordance with the Accounting Principles;
(iii) as soon as practicable following an acquisition or disposal of Notes by a Group Company, information regarding the aggregate Nominal Amount held by Group Companies, or the amount of Notes cancelled by the Issuer;
(iv) any other information required by the Swedish Securities Markets Act (Sw: lag (2007:582) om vardepappersmarknaden)
19(43)
and if applicable the rules and regulations of the MTF or other Regulated Market on which the Notes are admitted to trading.
(b) The Issuer shall immediately notify the Noteholders and the Agent upon becoming aware of the occurrence of a Change of Control Event or an Insurance Event. Such notice may be given in advance of the occurrence of a Change of Control Event and be conditional upon the occurrence of a Change of Control Event, if a definitive agreement is in place providing for such Change of Control Event.
(c) The Issuer shall in writing and no later than ten (10) Business Days from the date on which the liquidator has completed the Liquidation and Optineo has been dissolved, notify the Noteholders and the Agent that the Liquidation has been completed and provide a confirmation that Sutaren 14 is the owner of the real property Helsingborg Sutaren 14.
(d) The Issuer shall immediately notify the Noteholders and the Agent of (i) any change to the Issuer's or any Guarantor's management or board of directors, (ii) a change of auditor or auditing firm and (iii) any legal action, arbitration proceeding or other proceeding initiated or filed by or against the Issuer or any Guarantor provided that it could result in an Material Adverse Effect.
